Becker’s Healthcare Podcast: Tracking Insurance Policy Shifts and Payer Strategy with Jakob Emerson
Release Date: August 8, 2025
Introduction
In the latest episode of Becker’s Healthcare Podcast, hosted by Scott Becker, the discussion centers around the dynamic landscape of insurance policy shifts and payer strategies within the U.S. healthcare system. Scott is joined by Jakob Emerson, a seasoned expert in payer issues, to delve into the current trends, challenges, and strategic responses shaping the insurance industry.
1. Insurance Rate Increases: The Arkansas Case Study
Jakob Emerson opens the conversation by highlighting significant rate increase proposals from major insurers in Arkansas. He states:
“We’re seeing massive rate proposals across all the states, a 54% rate increase from Centene in Arkansas alone. [00:58]”
Emerson emphasizes that Arkansas Governor Sarah Huckabee Sanders has publicly condemned these proposed hikes, labeling them as “insane” and urging the state’s insurance commissioner to reject them. This situation exemplifies the broader national trend where insurers are proposing substantial rate increases amidst political and economic pressures.
Key Points:
- Centene and Blue Cross Blue Shield have proposed significant rate hikes for ACA plans in Arkansas.
- Governor Sanders is actively opposing these increases, reflecting a state-level pushback against insurers.
- The rate increases are partly driven by anticipated discontinuation of enhanced ACA premium tax credits.
2. Broader Implications of Insurance Rate Hikes
Scott Becker reflects on the broader issue of rising insurance costs, noting:
“People are talking about rate hikes of 15, 20% or more, at a time when health insurance seems like it’s gotten impossibly expensive for so many people. [04:09]”
He underscores the complexity of the problem, pointing out that while ACA-related factors contribute, there are additional elements at play, including rising medical costs and increased utilization rates. Emerson adds that the anticipated reduction in premium tax credits under a Republican-controlled Congress is a significant driver behind these rate hikes, though it represents only a portion of the overall increase.
Key Points:
- Rate hikes are occurring both within and outside the ACA framework.
- Factors beyond tax credits, such as overall medical cost inflation and increased utilization, are major contributors.
- The political landscape, especially Republican control at the federal level, influences these trends.
3. State vs. Federal Policy Dynamics
Emerson discusses the contrasting actions at state and federal levels:
“At the local level or the state level, Republican governors are coming out against the insurance companies for proposing higher rates... but at the federal level, it's Republican leaders that are holding up a possible extension to help alleviate some of those rates.” [00:58]
He highlights Arkansas as a focal point for progressive insurance policies, including attempts to regulate pharmaceutical benefit managers (PBMs). However, recent legal setbacks have impeded these efforts, illustrating the challenges of implementing state-level reforms in a complex federal system.
Key Points:
- State governments, particularly Republican-led ones like Arkansas, are actively challenging insurer rate hikes.
- Federal actions, or lack thereof, by Republican leaders can counterbalance state efforts.
- Legal battles, such as those involving PBMs, showcase the contentious nature of insurance regulation.
4. Federal Coverage Policies: IVF and GLP-1s
The conversation shifts to federal coverage policies, with Emerson noting two significant developments:
-
In Vitro Fertilization (IVF) Coverage:
“Back when President Trump was running for his second term, he had pledged that he was going to be requiring commercial insurance companies to provide coverage for in vitro fertilization services... there is no plans within the White House at this point to move forward with that type of plan. [05:29]”
Emerson explains that the anticipated federal mandate for IVF coverage is no longer in motion, leaving insurers without this potential coverage requirement.
-
GLP-1s for Weight Management:
“CMS wants to allow state Medicaid programs and Medicare Part D plans to cover GLP-1s for weight management on a voluntary basis. [07:30]”
He contrasts this with previous proposals to include anti-obesity medications under Medicare and Medicaid, which were ultimately not implemented. The renewed interest from CMS indicates an evolving stance on covering these expensive yet clinically promising medications.
Key Points:
- Federal mandates for IVF coverage have been shelved, removing a potential policy driver for insurer coverage.
- CMS is reconsidering the voluntary coverage of GLP-1s for weight management, reflecting ongoing debates about addressing obesity through medication coverage.
- The economic feasibility of covering such treatments remains a critical factor.
5. Economic Implications and Market Responses
Scott Becker provides an analysis of the economic challenges associated with these coverage decisions:
“An IVF cycle for a patient might cost $20, $25,000 a year or a cycle. There’s no way the federal government can end up covering that. [07:30]”
He contrasts this with GLP-1s, which primarily involve medication costs without the extensive labor and management required for IVF. This distinction underscores the differing economic impacts of covering various treatments.
Emerson highlights strategic responses from insurers, particularly Cigna’s approach to the GLP-1 market:
“Cigna really seems to be the leader of the pack here in terms of how they’re building their position as a key player in this high demand weight loss market. [08:56]”
Cigna is leveraging both its health plan and pharmacy benefits divisions to innovate in drug access and payment models, including requiring lifestyle modifications as a condition for coverage. This strategy aims to balance cost savings with clinical effectiveness, making GLP-1s more financially viable for both insurers and patients.
Key Points:
- The high cost and complexity of procedures like IVF make federal coverage impractical.
- GLP-1 medications present a different economic scenario with potentially manageable costs.
- Insurers like Cigna are pioneering models to integrate GLP-1 coverage with supportive programs to ensure cost-effectiveness and patient adherence.
6. Strategic Insights: Cigna’s Role in the Weight Loss Market
Emerson delves deeper into Cigna’s initiatives:
“They’re using both their health plan and their pharmacy benefits arm under Evernorth and Express Scripts to launch a lot of new models on how these drugs are accessed, how they’re paid for and ultimately how they’re controlled through... [08:56]”
He notes that approximately 50% of Cigna’s PBM clients now opt to cover GLP-1s for weight loss, indicating a significant uptake and acceptance of this approach within the market. This move positions Cigna as a leader in addressing the high-demand area of weight management through innovative insurance solutions.
Key Points:
- Cigna’s integrated approach leverages multiple facets of its business to enhance GLP-1 accessibility.
- The partnership between health plans and pharmacy benefits managers (PBMs) facilitates new payment and access models.
- A substantial portion of Cigna’s PBM clients are adopting GLP-1 coverage, reflecting market confidence in this strategy.
Conclusion
The episode concludes with Scott Becker expressing his appreciation for Jakob Emerson’s insights:
“Jacob, always a pleasure to visit with you. I always learned so much. I hope our audience does too.” [10:23]
Emerson’s comprehensive analysis sheds light on the intricate interplay between state and federal policies, economic constraints, and strategic insurer responses shaping the current and future landscape of healthcare insurance. As insurers navigate these challenges, innovations like Cigna’s models for GLP-1 coverage offer potential pathways to balancing cost, access, and quality in patient care.
Notable Quotes:
- Jakob Emerson [00:58]: “We’re seeing massive rate proposals across all the states, a 54% rate increase from Centene in Arkansas alone.”
- Scott Becker [04:09]: “People are talking about rate hikes of 15, 20% or more, at a time when health insurance seems like it’s gotten impossibly expensive for so many people.”
- Jakob Emerson [07:30]: “There is no plans within the White House at this point to move forward with that type of plan.”
- Scott Becker [07:30]: “An IVF cycle for a patient might cost 20, 25,000 a year or a cycle. There’s no way the federal government can end up covering that.”
This episode of Becker’s Healthcare Podcast provides a nuanced exploration of the challenges and strategic maneuvers within the insurance sector, offering valuable insights for healthcare professionals, policymakers, and stakeholders navigating the evolving landscape of U.S. healthcare.